Carisma Therapeutics Inc. Logo

Carisma Therapeutics Inc.

Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.

CARM | US

Overview

Corporate Details

ISIN(s):
US14216R1014 (+2 more)
LEI:
Country:
United States of America
Address:
3675 MARKET STREET, 19104 PHILADELPHIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company pioneering the development of engineered cell therapies. The company utilizes its proprietary macrophage and monocyte cell engineering platform to create first-in-class Chimeric Antigen Receptor Macrophage (CAR-M) therapeutics. These therapies are designed to leverage the unique abilities of macrophages to infiltrate solid tumors, directly kill cancer cells via targeted phagocytosis, and activate a broad anti-tumor immune response. Carisma is building a pipeline of programs focused on treating serious disorders, including solid tumors, fibrosis, and autoimmune diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Carisma Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Carisma Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Carisma Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea
335810
Prelude Therapeutics Inc Logo
Clinical-stage oncology company developing novel protein degraders and ADCs for cancer.
United States of America
PRLD
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea
334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore
950210
Prestige Consumer Healthcare Inc. Logo
Develops and markets leading over-the-counter brands for personal healthcare and wellness.
United States of America
PBH
Processa Pharmaceuticals, Inc. Logo
Develops next-gen chemo and therapies for chronic and life-threatening diseases.
United States of America
PCSA
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea
296160
PROKIDNEY CORP. Logo
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
United States of America
PROK
ProMIS Neurosciences Inc. Logo
Developing selective antibody therapies targeting toxic proteins in neurodegenerative diseases.
United States of America
PMN
Propanc Biopharma, Inc. Logo
Developing proenzyme therapies to prevent solid tumor recurrence and metastasis.
United States of America
PPCB

Talk to a Data Expert

Have a question? We'll get back to you promptly.